Kite Pharma Inc. — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

1 Recruiting

12 Completed trials

11 Countries active

44 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 3 Phase II: 7 Phase I: 2 Phase I (Other): 1

Oversight events:

9 temporary halts 5 corrective measures across 5 trials

View oversight register →

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

B-cell lymphoma refractory 1 Mantle cell lymphoma refractory 1 Follicular lymphoma 1

Top IMPs

BREXUCABTAGENE AUTOLEUCEL 7 AXICABTAGENE CILOLEUCEL 4 IBRUTINIB 3 CYCLOPHOSPHAMIDE 2 DEXAMETHASONE 2 ACALABRUTINIB 1 ANITOCABTAGENE AUTOLEUCEL 1 BENDAMUSTINE HYDROCHLORIDE 1 BORTEZOMIB 1 CARFILZOMIB 1 CYTARABINE 1 DARATUMUMAB 1

All trials

13 total

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting

2023-507041-28-00 Phase II 7 countries AXICABTAGENE CILOLEUCEL; BREXUCABTAGENE AUTOLEUCEL; KITE-363
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Ended

2022-501489-24-00 Phase III 7 countries AXICABTAGENE CILOLEUCEL
Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Ended

2024-511188-26-00 Phase III 9 countries ANITOCABTAGENE AUTOLEUCEL; BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; …
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with… Ended

2024-511616-24-00 Phase I 2 countries
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Phase III 4 countries AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; DOXORUBIC…
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Phase II 7 countries BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Phase II 7 countries BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Phase II 7 countries BREXUCABTAGENE AUTOLEUCEL
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Phase II 7 countries BREXUCABTAGENE AUTOLEUCEL
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Ended

2023-507748-35-00 Phase I 2 countries
A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lympho… Ended

2023-509440-97-00 Phase I (Other) 6 countries BREXUCABTAGENE AUTOLEUCEL
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended

2023-505169-10-00 Phase II 1 country AXICABTAGENE CILOLEUCEL
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Phase II 4 countries ACALABRUTINIB; BREXUCABTAGENE AUTOLEUCEL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETH…

Showing 1–13 of 13 trials

← All sponsors A–Z